Osteonecrosis of the jaw among cancer patients in Denmark: risk and prognosis |
| |
| Institution: | 1. Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark;2. Department of Clinical Medicine, Aarhus University, Aarhus, Denmark;3. Resources and Innovation, The Danish Clinical Quality Program (RKKP) – National Clinical Registries, Aarhus, Denmark;4. Department of Oral and Maxillofacial Surgery, Aarhus University Hospital, Aarhus, Denmark;5. Department of Dentistry and Oral Health, Aarhus University, Aarhus, Denmark;1. Department of Stomatology, Shaoxing People’s Hospital, Shaoxing, Zhejiang Province, PR China;2. Department of Head Neck and Thyroid, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, Henan, PR China;1. Harvard School of Dental Medicine, Boston, Massachusetts, USA;2. Department of Plastic and Oral Surgery, Boston Children’s Hospital, Boston, MA, USA;3. Program in Global Surgery and Social Change (PGSSC), Harvard Medical School, Boston, MA, USA;1. Department of Oral and Maxillofacial Surgery, University of Florida Jacksonville, Jacksonville, FL, USA;2. Department of Maxillofacial Surgery, Sapienza University of Rome, Rome, Italy;3. Department of Head and Neck Surgery, Tata Medical Center, Kolkata, India;4. Department of Oral and Maxillofacial Surgery, University of Maryland, Baltimore, MD, USA;5. Department of Head and Neck Surgery, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina;1. Boston Children’s Hospital, Boston, Massachusetts, USA;2. Harvard School of Dental Medicine, Boston, Massachusetts, USA;3. Division of Gastroenterology, Hepatology and Nutrition, Boston Children’s Hospital, Boston, Massachusetts, USA;4. Division of Otolaryngology and Communication Enhancement, Boston Children’s Hospital, Boston, Massachusetts, USA;5. Department of Plastic and Oral Surgery, Boston Children’s Hospital, Boston, Massachusetts, USA |
| |
| Abstract: | Osteonecrosis of the jaw (ONJ) is a serious complication of anti-resorptive therapy used in the treatment of multiple myeloma and cancerous bone metastases. In this study, patients with either multiple myeloma or solid tumours with a simultaneous or subsequent record of anti-resorptive treatment or bone metastases were identified using population-based medical registries. These patients were followed for the outcome of ONJ. Considering death as a competing risk, the cumulative incidence of ONJ was estimated, overall and by cancer site. Patients who developed ONJ were followed for the outcome of death overall and by several risk factors for ONJ. A total of 33,975 cancer patients fulfilling the inclusion criteria were identified; 233 incidents of ONJ and a cumulative incidence of 1.9% (95% confidence interval 1.6–2.3%) over a maximum follow-up time of 7.5 years were observed. The 5-year cumulative incidence was 1.3% (95% confidence interval 1.2–1.6%) and varied by cancer site. There were 126 deaths among cancer patients with ONJ over a maximum follow-up time of 6.4 years, resulting in a 5-year mortality of 91% (95% confidence interval 81–97%). Mortality among patients with ONJ varied by cancer site, osteonecrosis stage, and by history of trauma to the mucosa. |
| |
| Keywords: | cohort studies denosumab diphosphonates epidemiology neoplasms osteonecrosis |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
